Innovent Starts China Trials of Two Biologic Drug Candidates
publication date: Sep 15, 2016
Innovent Biologics of Suzhou announced clinical trial news for two of its biologic drugs: the company has started a pivotal China Phase III clinical trial of its Humira biosimilar, and it received CFDA approval to begin trials of its PD-1 candidate, which Innovent hopes will prove to be a best-in-class candidate. In the last twelve months, Innovent has been approved to start trials of four biologic drugs, a major achievement for the five-year old company. All together, Innovent is working on twelve biologics, a combination of biosimilar and novel molecules. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.